@spleenwine90Worm Pena
-
Worm Pena posted an update 3 months, 3 weeks ago
reated advanced dMMR/MSI-H solid tumors. As the first single-domain PD-L1-targeting antibody administered by rapid subcutaneous injection, envafolimab has the potential to be a significant advance in the treatment of cancer. Trial registration ClinicalTrials.gov, NCT03667170. Registered 10 September 2018-Retrospectively registered,…[Read more]
-
Worm Pena became a registered member 3 months, 3 weeks ago